Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 3,400 shares, a drop of 65.7% from the August 15th total of 9,900 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 8,000 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 8,000 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the company’s shares are sold short.

Adlai Nortye Stock Performance

NASDAQ:ANL opened at $1.80 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $1.61 and its 200-day simple moving average is $1.81. Adlai Nortye has a fifty-two week low of $1.10 and a fifty-two week high of $3.89.

Analyst Ratings Changes

Separately, HC Wainwright cut shares of Adlai Nortye from a “buy” rating to a “neutral” rating in a report on Monday, June 2nd. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.00.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.